H epatosplenic T-cell lymphoma (HSTCL) is a rare subset of the peripheral T-cell lymphomas, with less than one hundred case reports in the literature. It has been estimated to contribute only 1.4% of all T-cell lymphomas. 1 It was first described as a separate entity amongst the peripheral/mature T-cell lymphomas in the 1990 REAL (Revised European American Lymphoma) classification. 2 It is characterised by malignant T-cell proliferation with a predisposition for the sinusoids of the liver, sinuses and red pulp of the spleen, and the sinuses of the bone marrow; expression of gammadelta (cd) (or less commonly alpha-beta) T-cell receptor (TCR) as part of the malignant T-cell clone; and a very aggressive clinical course with poor prognosis (median overall survival of 11 months), 3, 4 although a more recent report suggests improved outcome and survival with intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation. 5 HSTCL is more common among young males in their teenage years and in young adulthood. Approximately 10-20% of patients have a history of immunosuppression, either through treatment for malignancy (such as in Hodgkin Lymphoma or acute myeloid leukaemia), inflammatory conditions (e.g. infliximab use in inflammatory bowel disease), or solid organ transplants. 6, 7 The majority of patients have liver, spleen, and bone marrow involvement at presentation. As a result they tend to be jaundiced, anaemic, have prominent hepatosplenomegaly, minimal lymphadenopathy, and constitutional or 'B' symptoms. Thrombocytopaenia is commonly seen, although this may be part of a broader pancytopaenia. The cause of the cytopaenias is multifactorial: marrow infiltration, splenic sequestration, haemolytic anaemia, immunemediated thrombocytopaenia, or haemophagocytic syndrome either alone or in combination. Neutropaenia is less commonly encountered. Peripheral blood spill of malignant cells occurs in the leukaemic phase of the disease. 4, 7 The immunophenotype of the malignant cells is typically: CD2+, CD3+, cdTCR+, CD4À, CD5À, CD8À, CD±56. 8 An isochromosome of the long arm of chromosome 7 (i(7)(q10)) is a recurrent genetic abnormality described in HSTCL either in isolation or in association with other abnormalities, most notably trisomy 8, with the combination of these two abnormalities being highly suggestive of HSTCL. 9 There is no standard treatment regime that is described for this aggressive disease, and reported results of therapeutic interventions are generally disappointing and have limited efficacy. A variety of chemotherapeutic regimes have been used; from standard CHOP (cyclophosphamide, hydroxydaunorubicin, oncovin, prednisone), CHOP-like regimens, purine analogues, monoclonal antibodies (e.g. alemtuzumab), platinum-based regimes, ICE (ifosfamide, carboplatin, etoposide) and IVAC (ifosfamide, etoposide, highdose cytarabine). 5, 10 In the last decade, however, there have been a number of reports of the successful use of allogeneic stem cell transplants (SCT), which appears to be the only therapeutic intervention that has resulted in durable, long term remissions and potential cure of the disease. 5, 10, 11 There have been no case reports from South Africa with regard to HSTCL. Chris Hani Baragwanath Academic Hospital (CHBAH) is a tertiary referral centre in Soweto, Johannesburg. More than two thirds of the adult Non-Hodgkin lymphoma (NHL) patients seen at this hospital are immunocompromised (HIV seropositive) and harbour aggressive B-cell lymphomas such as diffuse large B-cell lymphoma, Burkitt lymphoma and plasmablastic lymphoma. 12 T-cell lymphomas are less common. We report three patients with HSTCL, seen over a three year period -January 2011-December 2013 at CHBAH.
CLINICAL PRESENTATION
Three patients with HSTCL were identified over a three-year period (1 January 2011-31 December 2013) at the adult Clinical Haematology unit, Department of Medicine, Chris Hani Baragwanath Academic Hospital. All three of these patients were male, of black ethnicity, and presented at a mean age of 29 years (range: 21-42 years). All were HIV seronegative, with no other history or evidence of immunosuppression. A summary of the clinical features of these patients at presentation is depicted in Table 1 . Of note is that all the patients had constitutional symptoms, hepatosplenomegaly and cytopaenias, but no significant lymphadenopathy. The laboratory features at presentation for the patients are summarised in Table 2 and depicted in Figs. 1-4 . All the patients showed abnormalities of their blood counts, with patient 3 presenting in a leukaemic phase of the disease. All the patients had malignant infiltration of their bone marrow. In addition, patient 1 had confirmed hepatic infiltration on liver biopsy with CD3+ tumour cells (liver biopsy was performed as his first bone marrow investigation did not yield a diagnosis, due to subtle infiltration).
DISCUSSION AND CONCLUSIONS
HSTCL is a rare subset of NHL. There are no reports in the literature of this entity being described in South Africa, despite lymphoma being the most common haematological malignancy in adults (the possibility of under-reporting of this entity cannot be excluded). The clinical presentation in the three patients seen at CHBAH is similar to that reported in the literature, with hepatosplenomegaly, minimal lymphadenopathy, constitutional symptoms, and cytopaenias. All patients had infiltration of bone marrow, spleen, and liver at presentation, although the degree of infiltration varied. Patient 3 presented in the leukaemic phase of the disease with evidence of disease in the peripheral blood, more profound cytopaenias, and a very poor performance status (PS = 4).
In addition to supportive care, the patients received combination chemotherapy, as indicated in Table 1 . Despite the use of a number of different combination chemotherapy regimens in patients 1 and 2, neither of the patients achieved a complete remission and both died of refractory disease, with a mean survival of 7.5 months. Patient 3 presented in the leukaemic phase of the disease and demised shortly after initiating chemotherapy and was thus inevaluable. None of the three patients were considered for or were candidates for SCT.
Prior to the use of allogeneic SCT, the literature shows the limited efficacy and uniformly poor outcome of patients treated with a variety of chemotherapeutic interventions. 10 However, recent reports suggest a better outcome with SCT, 5, 10, 11 particularly with the use of intensive induction chemotherapy followed by early high-dose therapy and hematopoietic SCT. 5 Clinicians, including haematologists, oncologists and pathologists need to be aware of this rare, aggressive form of NHL, so that a diagnosis can be readily established and the patient managed aggressively, with early consideration of SCT -the only potentially curative intervention in patients with HSTCL. Additionally, a multi-centred approach is advised, with pooling of patient data and the use of a uniform therapeutic approach, in order to explore and optimise the management of patients with this rare form of T-cell lymphoma.
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